Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naveglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 19/20 | 1.00 |
| ▸ | PPARA known ✓ | Q07869 | 19/20 | 1.00 |
| ▸ | PPARD | Q03181 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naveglitazar SCHEMBL5374978 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL677199 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| Naveglitazar SCHEMBL5383187 | 0.99 | PPARG (0.97) | PPARGPPARAPPARD | |
| SCHEMBL5380701 | 0.97 | PPARG (0.95) | PPARGPPARAPPARD | |
| SCHEMBL5375478 | 0.96 | PPARG (0.93) | PPARGPPARAPPARD | |
| SCHEMBL5382474 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5382488 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5375774 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL5394822 | 0.92 | PPARG (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383883 | 0.92 | PPARA (0.84) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20080070958-A1 | Therapeutic Agent for Keratoconjunctival Disorder | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-20 | — | — | US | claimed |
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | claimed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4743451-A1 | TROMETHAMINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO Pharma (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743450-A1 | L-LYSINE SALT OF 4-CHLORO-5-[4-(2,6-DICHLOROPHENYL)SULFONYLPIPERAZIN-1-YL]-1-BENZOFURAN-2-CARBOXYLIC ACID AND VARIOUS FORMS THEREOF | ENYO Pharma (FR) | 2026-05-20 | — | — | EP | disclosed |
| WO-2006094933-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| JP-2006104199-A | AGENT FOR TREATMENT OF KERATOCONJUNCTIVE DISORDER | SANTEN PHARMACEUT CO LTD | 2006-04-20 | — | — | JP | disclosed |
| WO-2006030753-A1 | THERAPEUTIC AGENT FOR KERATOCONJUNCTIVA DISORDER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138998-A1 | GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | GLP1R, GIPR, GPR119 | PPARG 326/4885PPARA 599/4885PPARD 793/4885 |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 7/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | PPARG 567/4885PPARA 787/4885PPARD 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.